You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, January 2023
|
| DOI | 10.1136/jitc-2022-005871 |
| Pubmed ID | |
| Authors |
Viktoria Marquardt, Johanna Theruvath, David Pauck, Daniel Picard, Nan Qin, Lena Blümel, Mara Maue, Jasmin Bartl, Ulvi Ahmadov, Maike Langini, Frauke-Dorothee Meyer, Allison Cole, Joselyn Cruz-Cruz, Claus M Graef, Matthias Wölfl, Till Milde, Olaf Witt, Anat Erdreich-Epstein, Gabriel Leprivier, Ulf Kahlert, Anja Stefanski, Kai Stühler, Stephen T Keir, Darell D Bigner, Julia Hauer, Thomas Beez, Christiane B Knobbe-Thomsen, Ute Fischer, Jörg Felsberg, Finn K Hansen, Rajeev Vibhakar, Sujatha Venkatraman, Samuel H Cheshier, Guido Reifenberger, Arndt Borkhardt, Thomas Kurz, Marc Remke, Siddhartha Mitra |
X Demographics
The data shown below were collected from the profiles of 24 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 25% |
| India | 1 | 4% |
| Paraguay | 1 | 4% |
| Germany | 1 | 4% |
| France | 1 | 4% |
| Colombia | 1 | 4% |
| Israel | 1 | 4% |
| Unknown | 12 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 17 | 71% |
| Scientists | 4 | 17% |
| Practitioners (doctors, other healthcare professionals) | 2 | 8% |
| Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 25 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Unspecified | 6 | 24% |
| Researcher | 3 | 12% |
| Student > Bachelor | 2 | 8% |
| Student > Master | 2 | 8% |
| Student > Ph. D. Student | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 9 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Unspecified | 6 | 24% |
| Chemistry | 3 | 12% |
| Biochemistry, Genetics and Molecular Biology | 2 | 8% |
| Medicine and Dentistry | 2 | 8% |
| Agricultural and Biological Sciences | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 10 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 105. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 February 2023.
All research outputs
#408,648
of 25,707,225 outputs
Outputs from Journal for Immunotherapy of Cancer
#86
of 3,492 outputs
Outputs of similar age
#9,713
of 479,072 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#6
of 144 outputs
Altmetric has tracked 25,707,225 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,492 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 479,072 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 144 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.